Christopher Kiff

What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma

S. Klijn, Elisabeth Fenwick, Sonja Kroep et al. · PharmacoEconomics · 2021 · 28 citations

Medicine, Immunology, Oncology +14

Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England

Ben Rothwell, Christopher Kiff, C. Ling et al. · PharmacoEconomics - Open · 2020 · 25 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17

A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions

James W. Shaw, Bryan Bennett, Andrew Trigg et al. · Value in Health · 2021 · 23 citations · Full text

Pharmacy, Biostatistics, Oncology +17

A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data Maturity

Tim S. Grant, Darren Burns, Christopher Kiff et al. · PharmacoEconomics · 2019 · 19 citations

Public Health, Biostatistics, Data Science +16